Safety Study of Cenderitide in Stable Chronic Heart Failure
Completed · Phase 2
Conditions studied: Heart Failure
In brief
Planned enrollment is approximately twelve subjects with stable chronic heart failure. Enrolled subjects will receive up to eight sequential days of continuous, stepwise, dose increasing, subcutaneous (SQ) infusions of open-label cenderitide via the Insulet Drug Delivery System. Planned infusion rates of cenderitide will be administered to subjects continuously during four, 48-hour infusion periods.
Key facts
- Study ID
- NCT02359227
- Run by
- Capricor Inc.
- People needed
- 14
- Starts
- 2015-01-01
- Expected to finish
- 2015-04-02
- Last updated by the study team
- 2020-02-11
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Orange County Research Center — Tustin, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.